Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.45 |
| ▸ | ATP4A | P20648 | 3/20 | 0.44 |
| ▸ | ATP4B | P51164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816326 | 0.79 | ATP4A (0.40) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4591400 | 0.79 | ATP4A (0.40) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5032825 | 0.75 | CYP19A1 (0.50) | CYP19A1ATP4AATP4B | |
| SCHEMBL1814676 | 0.74 | CYP3A4 (0.46) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4590723 | 0.73 | ATP4A (0.35) | ATP4AATP4BTDP1CYP3A4CYP2C9 | |
| SCHEMBL4590855 | 0.73 | ATP4A (0.33) | ATP4AATP4B | |
| SCHEMBL4591093 | 0.73 | ATP4A (0.33) | ATP4AATP4B | |
| SCHEMBL4590828 | 0.73 | ATP4A (0.35) | ATP4AATP4BTDP1CYP3A4CYP2C9 | |
| SCHEMBL5044812 | 0.71 | KIF11 (0.38) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4591100 | 0.71 | ATP4A (0.34) | ATP4AATP4BCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984969-B1 | FUSED DIHYDROPYRANS | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| EP-0984969-A1 | FUSED DIHYDROPYRANS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054188-A1 | FUSED DIHYDROPYRANS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-12-03 | — | — | WO | claimed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| EP-0984969-B1 | FUSED DIHYDROPYRANS | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005021040-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6160119-A | Fused dihydropyrans | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP19A1 4732/4885ATP4A 1096/4885ATP4B 1186/4885 |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP19A1 4732/4885ATP4A 1096/4885ATP4B 1186/4885 |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | HTR3A, HTR3D, HTR3B | CYP19A1 4722/4885ATP4A 1289/4885ATP4B 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.